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0.1016/j.jmig.2016.09.009Since the early 1980s [1], endometrial ablation has
become a successful treatment modality in the armamen-
tarium for the management of patients with heavy menstrual
bleeding (HMB; PALM-COEIN: E, O) who completed their
childbearing. Endometrial ablation is currently used world-
wide as a safe and less invasive alternative to hysterectomy.
Utilization of resectoscopic endometrial ablation/resection
modalities was and continues to be low because of the
high degree of technical complexity, requirement for
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curve, and the risks associated with the use of nonelectrolyte
solutions for uterine distention [2,3]. In an attempt to rectify
this persistent adoption problem, a number of
nonresectoscopic devices were developed and approved by
the US Food and Drug Administration (FDA). Using a
randomized controlled trial (RCT) design for each pivotal
trial, the effectiveness and safety of each method was
shown to be ‘‘noninferior’’ when compared with rollerball
endometrial ablation [4–13].
As a result, the use of endometrial ablation as a less inva-
sive alternative to hysterectomy grew significantly [14]. How-
ever, the impact of adoption of these procedures on the overall
number of hysterectomies in the United States is still unclear.
Some reports indicate that the total number of (inpatient) hys-
terectomies performed annually declined to 433 621 cases in
2010 [15]. Other reports suggest the total number of inpatient
and outpatient hysterectomies remained static, at approxi-
mately 600,000 cases a year [16]. Questions and concerns
have been raised about high subsequent additional surgical re-
intervention rates, such as reablation and/or hysterectomy
performed for recurrent HMB and/or new pelvic pain. These
rates are reported to range between 16% and 24% [17–21].
TheMinerva Endometrial Ablation System (Minerva Surgi-
cal, Inc., Redwood City, CA) was developed as an attempt to
improve outcomes by using a novel technologic approach.
Starting in 2015, the FDA adopted a new clinical trial design
methodology, introducing the Objective Performance Criterion
as the study control [22], which represents a composite of suc-
cess rates for all previously FDA-approved nonresectoscopic
endometrial ablation systems (ThermaChoice, NovaSure, Gen-
esys HTA, Her Option, and MEA) as reported in their respec-
tive FDA trials. The Minerva Endometrial Ablation System is
the first device to be evaluated and approved by the FDA using
this newObjective Performance Criterion control [23]. Clinical
results reported in this single-arm Objective Performance Cri-
terion controlled study demonstrated that at the 12-month
follow-up, the Minerva Endometrial Ablation System is safe
and effective while producing results that were statistically
significantly superior when compared with the Objective Per-
formance Criterion control and published elsewhere [24].
This research effort had the goal of being a validator of previ-
ous clinical results [24] in a rigorous RCT environment.Methods
This study was conducted under an FDA-approved Inves-
tigational Device Exemption (G110215) and was sponsored
by Minerva Surgical, Inc. This investigation was a random-
ized, double-arm, multicenter, controlled, international study,
with rollerball ablation serving as the control. The study was
conducted at a total of 13 academic (n 5 8) and private
(n5 5) medical centers in the United States (n5 8), Canada
(n5 4), and Mexico (n5 1) and in full compliance with the
International Conference on Harmonization and Good Clin-
ical Practices, including recommendations guiding physi-cians in biomedical research involving human subjects
adopted by the 18th World Medical Assembly, Helsinki,
Finland, 1964 and later revisions, and standard ISO14155.
In accordance with federal requirements and existing prac-
tices [25,26], study progress was monitored by a Data
Safety Monitoring Board and a Clinical Events Committee.Clinical Protocol
The primary objective of the study was to evaluate the
safety and effectiveness of the Minerva Endometrial Ablation
System (Test) as compared with hysteroscopic rollerball abla-
tion (Control) in reducing menstrual blood loss as measured by
the alkaline hematin (AH)method at 12months post-treatment
and the occurrence of any adverse events (AEs). Study success
was defined as a reduction in menstrual bleeding from
R160 mL pretreatment to %80 mL at 12 months post-
treatment. Secondary objectives included amenorrhea rate
and treatment parameters (procedure time, anesthesia type).
Patient satisfaction was assessed using a patient survey and a
validated Menstrual Impact Questionnaire [27].
The effect of ablation on premenstrual syndrome (PMS)
symptoms was evaluated by collecting symptom data at base-
line and at 12 months after the procedure. Subjects were also
asked if they experienced dysmenorrhea. At baseline, the avail-
able answers were binary in nature (yes or no). To assess the
impact of ablation on dysmenorrhea, subjects who answered
yes were evaluated again at 12 months. If dysmenorrhea later
developed in subjects who did not report it at baseline, data
on such effects were collected and categorized as an AE.
Uterine sound and uterine cavity lengths, cervical dilation,
and the position of the uterus were recorded. Investigators were
required to rate theMinerva devicewith respect to general ease
of use, device insertion, deployment, ability to seal the cervical
canal, device removal, and overall user satisfaction.
All subjects qualifying for study participation and treat-
ment were block randomized from a centralized electronic
patient database in a 2:1 scheme to either the Test or Control
Group. The subjects were further stratified by baseline age
(%40 and .41 years). Endometrial pretreatment was not
used in the Minerva randomized subjects, whereas wire
loop resection of the endometrium was used as a mechanical
means of endometrial pretreatment for subjects randomized
to the rollerball arm of the study.
Clinical sites, investigators, and research staff were selected
based on their qualifications and experience, including having
significant experience in conducting clinical research, adequate
facilities, and the ability to comply with all scientific, regulato-
ry, and ethical site selection requirements. The main surgical
prerequisite for study participation was significant experience
in conducting resectoscopic surgery (rollerball ablation, endo-
metrial resection, other). At the time of study initiation, study
investigators had an average of 22.86 3.6 years of experience
in performing these procedures.
Fig. 1
Minerva Endometrial Ablation System.
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As required by the FDA, a formal Statistical Analysis
Plan (SAP) was developed and approved before study initi-
ation. The SAP outlined strict definitions and rules regarding
safety and effectiveness analysis, subject accountability,
missing data, and other procedures.
The study sample size was computed to yield at least 80%
power to demonstrate noninferiority (noninferiority margin
of 20%) of Minerva to rollerball, according to the approach
described by Farrington and Manning [28]. Based on a 1-
tailed test of proportions with a (Type 1 error) equal to
.025, and success rates in the rollerball arm (Control) of
80% and in the Minerva arm (Test) of 81%, the required
sample size was 129 subjects (86 Test and 43 Control).
Based on a projected 16% loss-to-follow-up rate, a total of
up to 153 subjects (102 Test and 51 Control) was enrolled.
The null hypothesis specified that the clinical success rate
for the Test device be inferior to the Control device by more
than the noninferiority margin of 20%. Rejecting the null hy-
pothesis indicates that the clinical success rate for the Test de-
vice is not less effective than the Control by more than the
noninferiority margin of 20%. The SAP specified that superi-
ority of the Test over the Control devicewould be tested in the
case that noninferiority is claimed. All primary effectiveness
and safety results were summarized for the intent-to-treat
population, defined as all subjects randomized and in whom
treatment was attempted, whether successful or not.
The study of the Minerva System was conducted at 13
clinical sites. Pooling the data was justified by implementa-
tion of identical protocols, data-gathering methods, and
study compliance monitoring across all clinical sites, with
the methodology described by Meinert [29]. In addition,
the FDA requires a test of homogeneity of odds ratios across
investigational sites. The test for homogeneity was based on
a 2-sided test at the .10 level of significance.
Demographic and baseline characteristics were summa-
rized descriptively. Additional statistical analyses were con-
ducted in strict compliance with the SAP. Data analysis was
performed by independent biostatisticians (R.P. Chiacchier-
ini Consulting, Gaithersburg, MD, and Willes Consulting
Group, Inc., Encinitas, CA) using SAS version 9.2 or later
(SAS Institute Inc., Cary, NC).Menstrual Blood Loss Assessment
Menstrual blood loss was quantitatively measured for
study inclusion and postoperatively at 6 and 12 months post-
procedure. Various feminine sanitary product brands (Kotex
Maxi Pads [Kimberly-Clark , Irving, TX], Tampax Flushable
Tampons [Procter & Gamble, Cincinnati, OH], Carefree
Original and Body Shape Pantiliners [Johnson & Johnson,
New Brunswick, NJ]) were supplied to each study subject,
and a validated AH analysis method [30,31] successfully
applied in a large number of other similar studies [32–34]
was used. Study subjects were required to collect usedsanitary products and blood clots using a special sanitary
product collection kit. The used sanitary products were
delivered to and inventoried by the clinical site before
being shipped to a central laboratory (KCAS Bioanalytical
Services, LLC, Shawnee, KS), which performed the AH
analysis of the menstrual sanitary products.Inclusion and Exclusion Criteria
Subjects were required to be premenopausal (follicle-stim-
ulating hormone level % 40 mIU/mL), between 25 and
50 years of age, to have completed childbearing, and to pro-
vide AH documented evidence of HMB (PALM-COEIN: E,
O). Bleeding levels were assessed preoperatively, and all can-
didates had to satisfy a minimum bleeding level of 160 mL
per cycle (for 1 cycle) to qualify for study participation. Uter-
ine sounding length was limited to amaximum of 10 cm. Dur-
ing the follow-up period, subjects were prohibited from using
any form of hormonal birth control to eliminate the possibility
of post-treatment bleeding reduction induced by the suppres-
sive action of hormonal contraceptives.
Evidence of pelvic inflammatory disease, active/acute
endometritis, sexually transmitted infections, bacteremia,
sepsis, other active local and/or systemic infection, un-
treated/unevaluated cervical dysplasia (except CIN I),
endometrial hyperplasia, or known or suspected abdominal
or pelvic cancer were all exclusionary in this study. Sub-
jects with suspected or known coagulopathies, on anticoa-
gulation therapy, or diagnosed with congenital
malformations of the uterus, hysteroscopically or ultraso-
nographically confirmed fibroid(s) distorting the uterine
cavity, endometrial polyp(s) larger than 2 cm, or if less
than 6 weeks post-partum were excluded from study partic-
ipation. Subjects with a history of prior uterine surgery
(except low segment cesarean delivery) that interrupts the
integrity of the uterine wall (e.g., transmural myomectomy
or classical cesarean section), as well as those with the his-
tory of previous endometrial ablation were excluded from
study participation. Also excluded were subjects that had
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ana) and those that were on medications that could thin
the myometrial muscle, such as long-term steroid use
(except inhaler or nasal therapy for asthma).Minerva Endometrial Ablation System and Rollerball
Ablation
The Minerva Endometrial Ablation System (Fig. 1) is de-
signed to treat HMB in premenopausal women for whom
childbearing is complete. It consists of the Minerva Surgical
Radio Frequency Controller and the Endometrial Ablation
Disposable Handpiece. The system uses Argon plasma tech-
nology to ablate tissue using 3 simultaneous and complimen-
tary ablation methods: tissue-penetrating bipolar
radiofrequency energy, direct-contact thermal ablation
from membrane to tissue, and thermal ablation using the
heated remnant liquids (blood, saline, other) present in the
uterine cavity. Detailed description of the Minerva Endome-
trial Ablation System is available elsewhere [24].Table 1
Baseline demographics and gynecologic history
Subject characteristic Minerva (n 5 102)
Age, yr
Mean 6 SD (median) 42.6 6 4.2 (42.9
Range (min–max) 31.6–50.1
Race
American Indian or Alaskan Native 1 (1.0%)
Black or African American 3 (2.9%)
White 98 (96.1%)
Ethnicity
Hispanic or Latino 30 (29.4%)
Not Hispanic or Latino 72 (70.6%)
Body mass index, kg/m2
Mean 6 SD (median) 30.0 6 7.1 (29.7
Range (min–max) 16.6–52.1
Reproductive history
Gravida
Mean 6 SD (median) 3.1 6 1.7 (3)
Range (min–max) .0–10.0
Para
Mean 6 SD (median) 2.6 6 1.3 (3)
Range (min–max) .0– 9.0
Menstrual history
Regular cycle pattern 97 (95.1%)
Dysmenorrhea 57 (55.9%)
PMS 66 (64.7%)
AH value at baseline
Mean 6 SD (median) 310.2 6 169.0 (247
Range (min–max) 161.5–1120.0
Laboratory results, FSH, IU/L
Mean 6 SD (median) 7.5 6 5.5 (6.0)
Range (min–max) 1.0–30.0
SD 5 standard deviation; FSH 5 follicle-stimulating hormone.Rollerball ablation is a resectoscopic ablation technique
first described by Vancaille in 1989 [35]. Since then it has
been extensively evaluated in a large number of RCTs and
other studies demonstrating very good immediate and
long-term clinical results. As a result, rollerball ablation es-
tablished itself and has remained the gold standard, and it is
the procedure that served as a control for all subsequently
developed nonresectoscopic endometrial ablation technolo-
gies [4–13,36].Patients
In total, 153 subjects were enrolled at 13 clinical sites.
Subjects were randomized to the Test or Control Groups at
the time of study enrollment, and all subjects were treated
as per the randomization assignment. All 153 subjects
were treated: 102 subjects in the Minerva Endometrial Abla-
tion System Test Group and 51 subjects in the rollerball abla-
tion Control Group. Table 1 lists the baseline demographicsRollerball (n 5 51) p
) 42.5 6 4.7 (43.1) .97
32.3–49.3
0 (.0%) 1.00
2 (3.9%)
49 (96.1%)
15 (29.4%) 1.00
36 (70.6%)
) 28.8 6 5.3 (28.6) .28
19.8–40.6
3.3 6 1.5 (3) .65
.0–7.0
2.5 6 1.2 (2) .65
.0–6.0
48 (94.1%) 1.00
32 (62.7%) .49
35 (68.6%) .72
.5) 301.8 6 176.1 (249.0) .78
160.0–1026.1
8.0 6 6.3 (6.0) .60
2.0–35.3
Table 2
Operative procedure data
Parameter
Minerva
(n 5 102)
Rollerball
(n 5 51) p
Sounding
length, cm
Mean 6 SD
(median)
8.9 6 .7 (9.0) 8.8 6 .7 (9.0) .55
Range
(min–max)
6.0–10.0 7.0–10.0
Cavity
length, cm
Mean 6 SD
(median)
5.4 6 .6 (5.5) 5.4 6 .6 (5.5) .90
Range
(min–max)
4.0–6.5 4.0–6.5
Cervical
dilation, mm
Mean 6 SD
(median)
6.8 6 1.1 (7.0) 9.3 6 1.5 (10.0) ,.0001
Range
(min–max)
.0–9.0 .0–10.0
Uterine position
Anteverted 68 (66.7%) 35 (68.6%) .52
Mid-position 15 (14.7%) 10 (19.6%)
Retroverted 19 (18.6%) 6 (11.8%)
SD 5 standard deviation.
Table 4
Rates of success and amenorrhea
Endpoint
Randomization arm
Minerva (n 5 102) Rollerball (n 5 51)
Success
n (%) 95 (93.1) 41 (80.4)
95% CI 86.4, 97.2 66.9, 90.2
Upper 97.5% CI
of the difference
–.80
p .02 (Fisher’s exact test)
Amenorrhea
n (%) 73 (71.6) 25 (49.0)
95% CI 61.8, 80.1 34.8, 63.4
p .01 (Fisher’s exact test)
CI 5 confidence interval.
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parameters were comparable between the treatment groups.
The homogeneity of the treatment effect across investiga-
tional sites at 12months of follow-upwas tested andwas not re-
jected (p5 .51). Because (1) the hypothesis of homogeneity ofTable 3
Anesthesia regimen
Anesthesia type
Randomization arm
Minerva (n 5 102) Rollerball (n 5 51)
General 19 (18.6) [11.6, 27.6] 10 (19.6) [9.8, 33.1]
General/cervical
block
0 (.0) [.0, 3.6] 1 (2.0) [.0, 10.4]
Intravenous 9 (8.8) [4.1, 16.1] 5 (9.8) [3.3, 21.4]
Intravenous/cervical
block
49 (48.0) [38.0, 58.2] 27 (52.9) [38.5, 67.1]
Intravenous/cervical
block/oral
7 (6.9) [2.8, 13.6] 3 (5.9) [1.2, 16.2]
Spinal block 7 (6.9) [2.8, 13.6] 0 (.0) [.0, 7.0]
Spinal block/
intravenous
11 (10.8) [5.5, 18.5] 5 (9.8) [3.3, 21.4]
Values are number of case with percents in parentheses and 95% confidence in-
tervals in brackets.treatment effect across sites was justified, (2) subjects were ran-
domized at each site, and (3) each investigational site conducted
the studyunder a commonprotocol, data could be pooled across
study sites to estimate a common treatment effect.Clinical Results
Procedure Data
The uterine sound and cavity lengths were comparable
between the 2 treatment groups, as were the various uterine
positions. Cervical dilation in the rollerball Control Group
was statistically significantly greater than that reported for
the Minerva Test Group (t test, p , .0001). Table 2 lists
data collected during the procedure for the 153 enrolled sub-
jects.
Study investigators were allowed to use the anesthesia
regimens commonly employed in their practice as the stan-
dard of care. Table 3 demonstrates that the anesthesia regi-
mens used were comparable between the treatment groups.
The mean procedure time, defined as the time from device
insertion to the time of device removal, for Minerva was
3.1 minutes, which was significantly less than the meanTable 5
Rates of success and amenorrhea as a function of age
Arm Age (yr)
Success Amenorrhea
n % p n % p
Minerva %40 34 94.4 .70 26 72.2 .91
411 61 92.4 47 71.2
Rollerball %40 13 72.2 .70 8 44.4 .75
411 28 84.8 17 51.5
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equal variance t test, p , .0001).Efficacy Results
The success rate at 1 year was 93.1% (95/102) for the
Minerva Test Group compared with 80.4% for rollerball,
with a difference of –12.7% and upper 1-sided 97.5% confi-
dence limit of –.80%. Thus, the noninferiority null hypothe-
sis was rejected because –.08% is lower than 20%. The test
for superiority of Minerva over rollerball was done and
concluded that the success rate in the Minerva Test Group
was statistically significantly greater than in the rollerball
Group (Fisher’s exact test, p 5 .02).
The amenorrhea rate at 1 year was 71.6% (73/102) for
the Minerva-treated subjects and 49% (25/51) for those
treated with rollerball, with this difference also achieving
statistical significance (Fisher’s exact test, p 5 .01)
(Table 4). Treatment failures included subjects with AH
values. 80 mL, subjects who had any additional (medical
and/or surgical) treatments or interventions for manage-
ment of HMB during the follow-up period, and any sub-
jects lost to follow-up.
The effect of age on success and amenorrhea for both treat-
ment groups was also analyzed. At 1 year post-treatment, the
success rates in the Minerva Test Group were 94.4% and
92.4% in the%40 and .40 age groups, respectively. At the
same 1-year time point, the rollerball Control subjects re-
ported success rates of 72.2% and 84.8%, respectively. The
amenorrhea rates in the %40 and .40 age groups were
72.2% and 71.2% for Minerva Test Group and 44.4% and
51.5% for rollerball Control Group, respectively (Table 5).
A logistic regression model for treatment success and amen-
orrhea rates was done and demonstrated that age did not
significantly affect success rates or amenorrhea rates either
by itself or in interaction with treatment.
During the first year of follow-up, 2 hysterectomies
(1.96%) were performed in the Minerva Group, whereas 3
hysterectomies (5.9%) were required in the rollerball arm
of the study. All hysterectomies (except 1 in the Minerva
arm) were performed for continuing bleeding. One MinervaTable 6
Number and percent of patients with serious AEs by time of occurrence
AE
Minerva (n 5 102)
0–14 Days of
procedure
15–30 Days of
procedure
.30 D
proced
Bleeding 0 (.0%) 0 (.0%) 0 (.0%
Endometritis 0 (.0%) 0 (.0%) 0 (.0%
Pelvic inflammatory
disease
0 (.0%) 0 (.0%) 1 (1.0
Other 1 (1.0%) 0 (.0%) 3 (2.9subject underwent hysterectomy because of pelvic inflam-
matory disease. A greater number of women in the rollerball
arm required additional medical (oral contraceptives, tra-
nexamic acid, Depo-Provera) and/or surgical treatment to
control bleeding at 1 year than in the Minerva arm. All sub-
jects who underwent hysterectomy were considered study
failures during analysis. The rate of (medical1 surgical) re-
intervention for HMB was 2.9% (95% confidence interval,
.6%–8.4%) in the Minerva group, compared with 11.8%
(95% confidence interval, 4.4%–23.9%) in the rollerball
group; however, this difference was not statistically signifi-
cant (Fisher’s exact test, p 5 .06).
At 12 months postprocedure, 53.5% of Minerva subjects
and 43.2% of rollerball subjects reported reduction in PMS.
Dysmenorrhea reduction was reported by 46.5% of Minerva
subjects and 45.5% of those treated with rollerball.Safety Results
The safety of both procedures was evaluated by recording
all AE. The numbers and percent of patients with serious
AEs by time of occurrence are presented in Table 6 and
nonserious AEs reported through the 12-month visit by de-
vice or procedural relationship are shown in Table 7. Inves-
tigators determined the relationship of the AE to the device
and/or procedure. An AE that was ‘‘possibly,’’ ‘‘probably,’’
or ‘‘highly probably’ related to the device or to the procedure
was considered ‘‘related.’’ Because no patient had more than
1 occurrence, Table 7 also represents the number of related
AE occurrences. There have been no unanticipated device-
related AEs in this study. All study participants adequately
complied with the protocol requirement for contraception
as evidenced by lack of unintended pregnancies during the
follow-up period.Patient Satisfaction
All subjects were asked about their level of satisfaction
with their endometrial ablation treatment. A significantly
higher rate of satisfaction was observed in the Minerva
group at 91.9% versus 79.5% reported by the rollerballRollerball (n 5 51)
ays of
ure
0–14 Days of
procedure
15–30 Days of
procedure
.30 Days of
procedure
) 1 (2.0%) 0 (.0%) 0 (.0%)
) 1 (2.0%) 0 (.0%) 0 (.0%)
%) 0 (.0%) 0 (.0%) 0 (.0%)
%) 0 (.0%) 1 (2.0%) 0 (.0%)
Table 7
Number and percent of patients with one or more related* AE by time of occurrence at 1 year
AE type Minerva (n 5 102) Rollerball (n 5 51)
Intraoperative AEs
Skin rash and/or itching or burning sensation 1 (1.0%) 0 (.0%)
Postoperative AEs (,24 h)
Bleeding or spotting 0 (.0%) 1 (2.0%)
Nausea and/or vomiting 0 (.0%) 1 (2.0%)
Weakness, fatigue, sleepiness, lack of concentration, dizziness 1 (1.0%) 0 (.0%)
Backache 1 (1.0%) 0 (.0%)
Fever 1 (1.0%) 0 (.0%)
Postoperative AEs (R24 h to 2 wk)
Abdominal pain and/or bloating 3 (2.9%) 1 (2.0%)
Pelvic pain 1 (1.0%) 0 (.0%)
Vaginal discharge and/or unpleasant vaginal smell or other abnormal sensation 1 (1.0%) 0 (.0%)
Weakness, fatigue, sleepiness, lack of concentration, dizziness 1 (1.0%) 1 (2.0%)
Constipation 0 (.0%) 1 (2.0%)
Endometritis or endomyometritis 1 (1.0%) 2 (3.9%)
Skin rash and/or itching or burning sensation 1 (1.0%) 1 (2.0%)
Postoperative AEs (.2 wk to 1 yr)
Abdominal pain and/or bloating 0 (.0%) 1 (2.0%)
Pelvic inflammatory disease 1 (1.0%) 0 (.0%)
Hematometra 1 (1.0%) 0 (.0%)
Dysmenorrhea 0 (.0%) 1 (2.0%)
* Possibly, probably, or highly probably related to device or procedure.
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.05). The subjects were also asked if they would recommend
the procedure to a friend or relative. At 1 year after the treat-
ment, 94.9% of the Minerva patients and 88.6% of the roll-
erball ablation patients reported they would recommend the
procedure to a friend or relative with a similar problem
(Fisher’s exact test, p 5 .28).Other Results
Use of the Minerva device was rated as ‘‘excellent’’ in
98% of cases, ‘‘good’’ in 1%, and ‘‘fair’’ in the remaining
1%. Investigators found the Minerva device to be easy to
insert and deploy and requiring minimal to no seating
manipulation. Utilization of the cervical sealing balloon
for the purpose of cervical canal occlusion during the Uter-
ine Integrity Test [24] was found to be adequate.Discussion
As with any RCT design, this study has a number of
strengths. The prospective study conduct allows for specific
allocation and administration of interventions to a chosen
population, thus reducing any allocation bias. Randomiza-
tion reduces selection bias and enables the variance of the
groups to be matched while reducing confounders. In addi-
tion, multicenter trials tend to have a greater clinical applica-
bility and effectively address the drawbacks of single-centerdesign studies, results of which are rarely confirmed and/or
replicated in an RCT environment. Use of the intent-to treat
approach in calculation of the primary and secondary end-
points with statistical methods clearly defined by the SAP
ensured that the reported outcome data are conservative in
nature. Subject retention in the study was good, with 6.5%
of subjects exiting the study before the 1-year follow-up.
This compares favorably with the reported loss to follow-
up rates of up to 18% in similar clinical trials [7,37,38].
The use of AH as a validated, quantitative, highly precise,
and accurate method for assessment of blood loss is a major
strength of this research. Methodologically, AH compares
favorably with the time-tested, but qualitative, binary in nature
(HMB vs non-HMB), and less accurate Pictorial Blood Loss
Assessment Chart method [39].
Aweakness of this study is that, like other similar studies,
this research effort does not represent core research on the
subject of the underlying medical condition but is rather
limited to assessment of safety and efficacy of 2 devices de-
signed to treat it. As such, the design of this and similar
studies cannot and should not be viewed as an attempt to bet-
ter understand the etiology and pathophysiology of HMB.
Another potential weakness of this study is related to a dis-
proportionally small enrollment of an African American
population when compared with its prevalence within US
population. Although there is no evidence that effectiveness
of endometrial ablation is race sensitive, having positive
proof of this in a study would be beneficial. Some may
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procedure rarely performed these days, has declining merit
and that a study comparing theMinerva amenorrhea and suc-
cess rates of 71.6% and 93.1%, respectively, to the FDA-
reported amenorrhea and success rates of today’s commonly
used endometrial ablation devices (NovaSure, 36% and
77.7% [12]; Genesys HTA, 35% and 68.4% [11]; and Her
Option, 22.2% and 67.4% [10]) would be of greater value.
We agree that such an RCTwould be of interest and should
be considered in the future.
Considering that patients suffering from coagulopathies
and those on anticoagulation therapy were excluded in this
study, a study assessing the performance of the Minerva sys-
tem in this subset of patient population is of interest and
should be considered as a subject of future research. The
relatively short duration of follow-up of only 12 months
can be viewed as a study weakness, because over a longer
period of time there may be an increase in the rate of treat-
ment failure, reintervention, and/or onset of dysmenorrhea,
effects reported with other endometrial ablation technolo-
gies [40]. Therefore, a longer-term follow-up for this study
is planned and once available will be reported.
The Minerva success rate of 93.1% is similar to the pre-
viously published Minerva Single Arm Study [24] success
rate of 96.2%, effectively validating and confirming the re-
sults of this previous research effort in a more rigorous
RCT environment. However, it is imperative to appreciate
that to duplicate the reported results, strict compliance
with all elements of patient selection criteria used in this
study is paramount. It should also be noted that Minerva suc-
cess rates were consistent and independent of the methodol-
ogies (Pictorial Blood Loss Assessment Chart vs AH) used
for the assessment of the primary endpoints of the studies
and/or overall study designs. The Minerva success rate of
93.1% is statistically superior to the success rate of 80.4%
reported in the rollerball arm of the study. This statistical su-
periority is believed to be the first such observation where a
nonresectoscopic endometrial ablation device was able to
outperform the gold standard rollerball efficacy in an RCT
setting. Therefore, we believe a confirmatory RCT vali-
dating these results would be of interest and benefit.
The Minerva reported amenorrhea rate of 71.6% was also
statistically superior when compared with that of rollerball
at 49% and is also in line with amenorrhea rate of 69.5% re-
ported in previous research [24]. Other research in the field
of endometrial ablation clearly suggests that amenorrhea
strongly correlates with high patient satisfaction [41],
whereas lack of amenorrhea commonly leads to hysterec-
tomy [42]. The rate of hysterectomy in the Minerva arm of
this study was lower than the rate in the rollerball arm. Pa-
thology reports indicated that in four of five subjects who un-
derwent hysterectomy, adenomyosis was present in the
extirpated specimen. Although this information is in line
with other clinical reports on this subject, we believe that
drawing unequivocal conclusions about the role of adeno-
myosis in the rate of failure and subsequent hysterectomy af-ter endometrial ablation is premature, because it is unclear
how many subjects with adenomyosis were successes in
this study and avoided hysterectomy. Patient satisfaction,
currently considered by many as the key performance data
point and the most important clinical validator of success,
was statistically significantly higher in the Minerva-treated
subjects than in the rollerball-treated subjects.
Reduction in PMS and dysmenorrhea was observed in
both arms of the study with no significant difference in the
degree of such reductions. Similarly to other studies that re-
ported on PMS and dysmenorrhea, the data derived on the
reported reduction did not use a validated questionnaire
and are qualitative in nature. Although fully expected and
reported in previous endometrial ablation related research
with these and other devices, the exact mechanism respon-
sible for these reductions remains unknown. Some investiga-
tors in this study theorized and elaborated on the possible
mechanisms behind these observations and presented them
elsewhere [24].
Procedure time for both procedures was short. On
average, the total time from device insertion to device
removal for Minerva was 3.1 minutes, which was signifi-
cantly less than the very respectable 17.2 minutes for roller-
ball. The degree of cervical dilation required to
accommodate the Minerva device was statistically less
than for rollerball, which has the potential of reducing the
incidence of unintended iatrogenic injuries (e.g., laceration)
to the cervix and/or the endocervical canal.
In conclusion, the results of this multicenter RCT demon-
strate that at 12-month follow-up the Minerva procedure
produces statistically significantly higher rates of success,
amenorrhea, and patient satisfaction as well as a shorter pro-
cedure time compared with the criterion standard rollerball
ablation. Safety results were excellent and similar for both
procedures. Results of this study replicate the results of pre-
viously published research, effectively confirming that the
Minerva procedure should be considered as a minimally
invasive treatment method when managing HMB unrelated
to anatomic causes.
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